What's Special About Speciality?
By Fintan Walton
Pharma Deals Review: Vol 2006 Issue 68 (Table of Contents)
Published: 1 Feb-2006
DOI: 10.3833/pdr.v2006.i68.565 ISSN: 1756-7874
Section: Business Commentaries
Fulltext:
Abstract
The continuance of M&A as dominating the deal making field was 'the buzz' at this year's JPMorgan Annual Healthcare Conference, particularly with biotech as the acquisition target. With the forecasted consolidation of biotech happening, and looking as if it will continue to happen in 2006, a question may be posed as to the likely status of emerging speciality companies and their remaining independence.
Copyright: © IQVIA 2018